SLC5A2 and diabetes mellitus: This study innovatively reveals that the application of a small dose of 5 mg SGLT2 inhibitors can reduce the risk of statins-induced abnormal blood glucose in non-diabetes patients with HFrEF after PCI, without increasing the risk of its common side effects.